Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03544866
Other study ID # ASP02172016
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 16, 2018
Est. completion date January 31, 2022

Study information

Verified date April 2022
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study leverages the availability of a validated series of instruments to measure the effect of highly visible, chronic skin disorders, including atopic dermatitis (AD), on patients 8 years of age and above in causing stigma and psychiatric issues, particularly anxiety and depression.


Description:

This is a multi center study with Northwestern University/Lurie Children's Hospital serving as the Data Coordinating Center. Site selection has been completed through members of PeDRA.


Recruitment information / eligibility

Status Completed
Enrollment 1666
Est. completion date January 31, 2022
Est. primary completion date May 31, 2021
Accepts healthy volunteers No
Gender All
Age group 8 Years to 17 Years
Eligibility Inclusion Criteria: - Subjects must be aged 8-17 years of age - Subject must be diagnosed with a chronic skin disease deemed to be severe enough and/or in a visible location that could be stigmatizing as determined by the study doctor - Subject and parent must both be English speaking with at least one parent/guardian who will complete the questionnaires - Subject and Parent/Guardian must be able to complete the relevant questionnaires Exclusion Criteria: - Children under 8 years of age - Children with developmental delay and/or a behavioral disorder that would preclude participation in form completion - Children with a non-cutaneous disorder that is considered by the Study doctor to be stigmatizing

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Department of Dermatology, Northwestern University Feinberg School of Medicine and Lurie Children's Hospital Chicago Illinois

Sponsors (4)

Lead Sponsor Collaborator
Northwestern University Immunex Corporation, Pediatric Dermatology Research Alliancce, Regeneron Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure the stigma experienced by children as a function of the child's perceived skin lesion visibility using the altered Neuro-QoL stigma tool Measure the stigma experienced by children as a function of the child's perceived skin lesion visibility using the altered Neuro-QoL stigma tool Past 7 days